Elanco Animal Health (ELAN) Director Acquires $251,022.50 in Stock

Elanco Animal Health (NASDAQ:ELAN) Director John P. Bilbrey purchased 7,750 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were acquired at an average price of $32.39 per share, for a total transaction of $251,022.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Elanco Animal Health stock traded up $0.48 during midday trading on Thursday, reaching $33.08. 2,186,459 shares of the stock were exchanged, compared to its average volume of 7,803,570. Elanco Animal Health has a 52 week low of $28.00 and a 52 week high of $37.61.

Elanco Animal Health (NASDAQ:ELAN) last posted its earnings results on Thursday, May 9th. The company reported $0.25 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.03. The firm had revenue of $731.10 million for the quarter, compared to the consensus estimate of $743.40 million. The business’s revenue was down .7% on a year-over-year basis. During the same period last year, the company posted $0.33 EPS.

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Elanco Animal Health in the 3rd quarter worth approximately $32,247,000. JPMorgan Chase & Co. acquired a new stake in Elanco Animal Health in the 3rd quarter valued at approximately $38,358,000. LPL Financial LLC acquired a new stake in Elanco Animal Health in the 3rd quarter valued at approximately $313,000. Legal & General Group Plc acquired a new stake in Elanco Animal Health in the 3rd quarter valued at approximately $839,000. Finally, Morgan Stanley acquired a new stake in Elanco Animal Health in the 3rd quarter valued at approximately $314,448,000.

ELAN has been the topic of a number of recent research reports. BMO Capital Markets upped their price target on shares of Elanco Animal Health from $32.00 to $35.00 and gave the company a “market perform” rating in a research note on Friday, May 10th. Zacks Investment Research cut shares of Elanco Animal Health from a “buy” rating to a “hold” rating in a research note on Tuesday, March 5th. UBS Group began coverage on shares of Elanco Animal Health in a research note on Wednesday, January 23rd. They set a “sell” rating and a $29.00 price target on the stock. Bank of America raised shares of Elanco Animal Health from a “neutral” rating to a “buy” rating and set a $30.95 target price on the stock in a report on Monday, March 18th. Finally, Morgan Stanley began coverage on shares of Elanco Animal Health in a report on Wednesday, March 13th. They set an “equal weight” rating and a $34.00 target price on the stock. One research analyst has rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the stock. Elanco Animal Health presently has an average rating of “Hold” and an average target price of $33.47.

COPYRIGHT VIOLATION WARNING: This article was first reported by Modern Readers and is the property of of Modern Readers. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.modernreaders.com/news/2019/05/16/elanco-animal-health-elan-director-acquires-251022-50-in-stock.html.

About Elanco Animal Health

There is no company description available for Elanco Animal Health Inc

See Also: Dividend Aristocrat Index

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.